K
Kwang Hyub Han
Researcher at Yonsei University
Publications - 694
Citations - 36674
Kwang Hyub Han is an academic researcher from Yonsei University. The author has contributed to research in topics: Hepatocellular carcinoma & Hepatitis B virus. The author has an hindex of 80, co-authored 692 publications receiving 30974 citations. Previous affiliations of Kwang Hyub Han include University Health System.
Papers
More filters
Journal ArticleDOI
Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy.
Mi Na Kim,Chun Kyon Lee,Sang Hoon Ahn,Sang Heun Lee,Seung Up Kim,Do Young Kim,Hyon Suk Kim,Kwang Hyub Han,Chae Yoon Chon,Jun Yong Park +9 more
TL;DR: The durability of the virological response after discontinuing lamivudine (LVD) in chronic hepatitis B patients with LVD‐resistant hepatitis B virus (HBV) patients who responded to LVD plus adefovir (ADV) combination therapy is examined.
Journal ArticleDOI
Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma.
TL;DR: Radiation dose with BED ≥72 Gy improved LFFR and PFR without increasing toxicity and should be actively considered to improve oncologic outcome in radiotherapy for incomplete TACE of HCC.
Journal Article
Clinical Features of Intestinal Behoet's Disease and Therapeutic Effects of Sulfasalazine
Journal ArticleDOI
Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B
Sangheun Lee,Jun Yong Park,Kijun Song,Do Young Kim,Beom Kyung Kim,Seung Up Kim,Hye Jin Ku,Kwang Hyub Han,Sang Hoon Ahn +8 more
TL;DR: The estimated glomerular filtration rate (eGFR) during telbivudine (LdT) versus entecavir (ETV) treatment in chronic hepatitis B (CHB) patients with underlying comorbidities such as diabetes mellitus, hypertension, and cirrhosis gradually increased over time, whereas a reduction was seen with ETV treatment.
Journal ArticleDOI
Continuing Besifovir Dipivoxil Maleate Versus Switching from Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B: Results of 192-Week Phase 3 Trial.
Do Seon Song,Won Kim,Sang Hoon Ahn,Hyung Joon Yim,Jae Young Jang,Young Oh Kweon,Yong Kyun Cho,Yoon Jun Kim,Gun Young Hong,Dong Joon Kim,Young Kul Jung,Joo Hyun Sohn,Jin-Woo Lee,Sung Jae Park,Byung Seok Lee,Ju-Hyun Kim,Hong Soo Kim,Seung Kew Yoon,Moon Young Kim,Kwan Sik Lee,Young-Suk Lim,Wan Sik Lee,Jin Mo Yang,Kyun-Hwan Kim,Kwang Hyub Han,Soon Ho Um +25 more
TL;DR: In this article, a 192-week extension study was conducted to evaluate the efficacy and safety of BSV in treatment-naive chronic hepatitis B patients, where patients continued to participate in an open-label BSV study after an initial 48-week double-blind comparison of the BSV and tenofovir disoproxil fumarate treatment.